Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,197,080 papers from all fields of science
Search
Sign In
Create Free Account
ABT-450
Known as:
ABT 450
, ABT450
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (1)
Macrocyclic Compounds
Narrower (1)
paritaprevir
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
In silico studies on therapeutic agents for COVID-19: Drug repurposing approach
Bhumi M. Shah
,
Palmi Modi
,
Sneha Sagar
Life Science
2020
Corpus ID: 215749068
Highly Cited
2015
Highly Cited
2015
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised…
C. Hézode
,
T. Asselah
,
+11 authors
S. Pol
The Lancet
2015
Corpus ID: 3874022
Highly Cited
2014
Highly Cited
2014
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
J. Feld
,
K. Kowdley
,
+11 authors
B. Bernstein
New England Journal of Medicine
2014
Corpus ID: 27000147
BACKGROUND The interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r) and the NS5A inhibitor…
Expand
Highly Cited
2014
Highly Cited
2014
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
F. Poordad
,
C. Hézode
,
+14 authors
B. Bernstein
New England Journal of Medicine
2014
Corpus ID: 23220044
BACKGROUND Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased…
Expand
Highly Cited
2014
Highly Cited
2014
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
P. Ferenci
,
D. Bernstein
,
+26 authors
K. Reddy
New England Journal of Medicine
2014
Corpus ID: 205096650
BACKGROUND The interferon-free regimen of ABT-450 with ritonavir (ABT-450/r), ombitasvir, and dasabuvir with or without ribavirin…
Expand
Highly Cited
2014
Highly Cited
2014
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
S. Zeuzem
,
I. Jacobson
,
+17 authors
B. Bernstein
New England Journal of Medicine
2014
Corpus ID: 23463907
BACKGROUND In this phase 3 trial we evaluated the efficacy and safety of the interferon-free combination of ABT-450 with…
Expand
Highly Cited
2014
Highly Cited
2014
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
P. Andreone
,
M. Colombo
,
+11 authors
B. Bernstein
Gastroenterology
2014
Corpus ID: 206233713
BACKGROUND & AIMS The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor…
Expand
Highly Cited
2014
Highly Cited
2014
An interferon-free antiviral regimen for HCV after liver transplantation.
P. Kwo
,
P. Mantry
,
+13 authors
X. Forns
New England Journal of Medicine
2014
Corpus ID: 24529974
BACKGROUND Hepatitis C virus (HCV) infection is the leading indication for liver transplantation worldwide, and interferon…
Expand
Highly Cited
2014
Highly Cited
2014
Therapy of hepatitis C--back to the future.
T. Liang
,
M. Ghany
New England Journal of Medicine
2014
Corpus ID: 205078575
A book on hepatitis C would read like a marriage of an Orson Welles mystery and a Shakespearean play — awash in enigma, tragedy…
Expand
Highly Cited
2013
Highly Cited
2013
Exploratory study of oral combination antiviral therapy for hepatitis C.
F. Poordad
,
E. Lawitz
,
+10 authors
B. Bernstein
New England Journal of Medicine
2013
Corpus ID: 205094777
BACKGROUND There is a need for interferon-free treatment regimens for hepatitis C virus (HCV) infection. The goal of this study…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE